Obesity and Low-Grade Inflammation Increase Plasma Follistatin-Like 3 in Humans
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Obesity and Low-Grade Inflammation Increase Plasma Follistatin-Like 3 in Humans. / Brandt, Claus; Pedersen, Maria; Rinnov, Anders; Andreasen, Anne S; Møller, Kirsten; Hojman, Pernille; Pedersen, Bente K; Plomgaard, Peter.
In: Mediators of Inflammation, Vol. 2014, 364209, 2014, p. 1-10.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Obesity and Low-Grade Inflammation Increase Plasma Follistatin-Like 3 in Humans
AU - Brandt, Claus
AU - Pedersen, Maria
AU - Rinnov, Anders
AU - Andreasen, Anne S
AU - Møller, Kirsten
AU - Hojman, Pernille
AU - Pedersen, Bente K
AU - Plomgaard, Peter
PY - 2014
Y1 - 2014
N2 - BACKGROUND: Rodent models suggest that follistatin-like 3 (fstl3) is associated with diabetes and obesity. In humans, plasma fstl3 is reduced with gestational diabetes. In vitro, TNF-α induces fstl3 secretion, which suggests a link to inflammation.OBJECTIVE: To elucidate the association between plasma fstl3 and obesity, insulin resistance, and low-grade inflammation in humans.STUDY DESIGN: Plasma fstl3 levels were determined in a cross-sectional study including three groups: patients with type 2 diabetes, impaired glucose tolerance, and healthy controls. In addition, lipopolysaccharide (LPS), TNF-α, or interleukin-6 (IL-6) as well as a hyperinsulinemic euglycemic clamp were used to examine if plasma fstl3 was acutely regulated in humans.RESULTS: Plasma fstl3 was increased in obese subjects independent of glycemic state. Moreover, plasma fstl3 was positively correlated with fat mass, plasma leptin, fasting insulin, and HOMA B and negatively with HOMA S. Furthermore plasma fstl3 correlated positively with plasma TNF-α and IL-6 levels. Infusion of LPS and TNF-α, but not IL-6 and insulin, increased plasma fstl3 in humans.CONCLUSION: Plasma fstl3 is increased in obese subjects and associated with fat mass and low-grade inflammation. Furthermore, TNF-α increased plasma fstl3, suggesting that TNF-α is one of the inflammatory drivers of increased systemic levels of fstl3.
AB - BACKGROUND: Rodent models suggest that follistatin-like 3 (fstl3) is associated with diabetes and obesity. In humans, plasma fstl3 is reduced with gestational diabetes. In vitro, TNF-α induces fstl3 secretion, which suggests a link to inflammation.OBJECTIVE: To elucidate the association between plasma fstl3 and obesity, insulin resistance, and low-grade inflammation in humans.STUDY DESIGN: Plasma fstl3 levels were determined in a cross-sectional study including three groups: patients with type 2 diabetes, impaired glucose tolerance, and healthy controls. In addition, lipopolysaccharide (LPS), TNF-α, or interleukin-6 (IL-6) as well as a hyperinsulinemic euglycemic clamp were used to examine if plasma fstl3 was acutely regulated in humans.RESULTS: Plasma fstl3 was increased in obese subjects independent of glycemic state. Moreover, plasma fstl3 was positively correlated with fat mass, plasma leptin, fasting insulin, and HOMA B and negatively with HOMA S. Furthermore plasma fstl3 correlated positively with plasma TNF-α and IL-6 levels. Infusion of LPS and TNF-α, but not IL-6 and insulin, increased plasma fstl3 in humans.CONCLUSION: Plasma fstl3 is increased in obese subjects and associated with fat mass and low-grade inflammation. Furthermore, TNF-α increased plasma fstl3, suggesting that TNF-α is one of the inflammatory drivers of increased systemic levels of fstl3.
KW - Adiponectin
KW - Adult
KW - Cross-Sectional Studies
KW - Follistatin-Related Proteins
KW - Humans
KW - Inflammation
KW - Insulin
KW - Interleukin-6
KW - Leptin
KW - Lipopolysaccharides
KW - Male
KW - Obesity
KW - Tumor Necrosis Factor-alpha
U2 - 10.1155/2014/364209
DO - 10.1155/2014/364209
M3 - Journal article
C2 - 25104880
VL - 2014
SP - 1
EP - 10
JO - Mediators of Inflammation
JF - Mediators of Inflammation
SN - 0962-9351
M1 - 364209
ER -
ID: 137630513